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Abstract
Introduction—Given the discordant prostate cancer screening recommendations in the United 
States, shared decision-making (SDM) has become increasingly important. The objectives of this 
study were to determine who made the final decision to obtain prostate-specific antigen (PSA)-
based screening and identify factors associated with the screening decision made by both patients 
and their health care providers.
Methods—Using the 2013 Behavioral Risk Factor Surveillance System data from Delaware, 
Hawaii, and Massachusetts, we calculated weighted percentages of SDM. Associations between 
the SDM and sociodemographic, lifestyle, access to care, and PSA testing-related factors were 
assessed using multivariate logistic regression.
Results—There were 2,248 men aged 40 years or older who ever had a PSA-based screening in 
these three states. Only 36% of them made their prostate cancer screening decision jointly with 
their health care provider. Multivariate analyses showed that men who were married/living 
together or had a college degree and above were more likely to report having SDM than men who 
were never married or had less than high school education (P = 0.02 and 0.002). Moreover, men 
whose most recent PSA test occurred within the past year were more likely to report SDM than 
men who had the test done more than 2 years ago (P = 0.02).
Conclusions—The majority of screening decisions were made by the patient or health care 
provider alone in these three states, not jointly, as recommended. Our study points to the need to 
promote SDM among patients and their health care providers before PSA testing.
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Introduction
Due to conflicting evidence for the effectiveness of the prostate-specific antigen (PSA) test 
in reducing mortality and the known potential harms, in 2012, the United States Preventive 
Services Task Force (USPSTF) recommended against routine PSA-based prostate cancer 
screening for men of all ages. In addition, the USPSTF recommends that physicians help 
patients who clearly express an interest in PSA testing make an informed decision before 
ordering a test [1, 2]. Currently, prostate cancer screening recommendations vary markedly 
among major medical societies in the United States [2–5]. However, informed or shared 
decision-making, a communication process on the benefits, harms, and scientific 
uncertainties of PSA testing conducted between health care providers and patients to help 
patients make value-concordant decisions about screening, has consistently been 
recommended [6].
National evidence indicated that only one-third of men reported ever having past discussions 
about advantages, disadvantages, and the scientific uncertainties of PSA-based screening 
with their health care providers [7]. Imbalanced discussions, which emphasize the advantage 
of the test more frequently and adequately than its disadvantages, have been well 
documented in the literature [7–10]. Information about who made the final decision to have 
a PSA test is scarce. In 2013, the Centers for Disease Control and Prevention collected data 
about prostate cancer screening decision-making through the Behavioral Risk Factor 
Surveillance System (BRFSS). The objectives of this study were to determine who made the 
final decision to obtain a PSA test and identify factors associated with shared decision-
making between patients and their health care providers.
Methods
This study used data from the 2013 BRFSS, a state-based telephone survey of health risk 
behaviors, preventive health practices, and health care access among the noninstitutionalized 
US civilian population aged 18 years or older in the 50 states and the District of Colombia 
(http://www.cdc.gov/BRFSS/). Delaware, Hawaii, and Massachusetts were the only states 
that collected information about prostate cancer screening decision-making among men aged 
40 years or older who ever had a PSA test and yielded response rates of 40.1, 40.2, and 
39.9%, respectively.
As shown in Appendix I, the primary outcome of this analysis was defined as a shared 
decision to screen determined by both men and their health care providers before ordering a 
PSA test (hereafter SDM). Briefly, SDM was classified as “yes” only for those responding C 
to Question 1 and A to question 2. Associations of the SDM (yes vs no) with 
sociodemographics (age, race/ethnicity, education, employment, and marital status), 
lifestyles (smoking and exercise), and access to care factors (have health insurance and 
regular health care provider) along with ever having discussed PSA testing (yes vs no) and 
time of receiving most recent test were examined (within a year, 1 year but less than 2 years, 
or 2 years and more). Survey questions about if ever been discussed the advantages and 
disadvantages of the PSA test and about the time, since the last PSA test were shown in 
Appendix II. We identified SDM for prostate cancer screening (not for cancer diagnostic or 
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surveillance purposes) based on responding A and C to survey question 4 in the Appendix II: 
“What was the Main reason you had this PSA test—was it…?”
We analyzed three states combined data using SAS-callable SUDAAN, version 9.3, to 
account for the multistage and disproportionate stratified sampling design. We conducted 
bivariate analysis to estimate unadjusted percentages of SDM with 95% confidence intervals 
(CIs) by the aforementioned characteristics. The main effect of the unadjusted percentage 
was assessed by the Chi-square test. Adjusted percentages with 95% CIs for SDM were 
calculated using multivariate logistic regression controlling for all covariables. Predicted 
margins for each subgroup were calculated from the logistic regression model as the average 
of the predicted probabilities of SDM, assuming that all survey participants were in that 
subgroup.
Results
As shown in Table 1, there were 2,248 men aged 40 years or older who ever had a PSA test 
for cancer screening in these three states in 2013. Among them, only 36% of men made their 
prostate cancer screening decision jointly with their health care providers; 25% of men made 
the decision on their own, and 37% of men had the decision made by their health care 
provider.
Bivariate analysis showed that shared decision-making for prostate cancer screening was 
associated with men’s educational attainment and marital status (Table 2). Multivariate 
analyses revealed that men who were married/living together or had a college degree and 
above were more likely to report having SDM on PSA testing than men who were never 
married or had less than high school education (P = 0.02 and 0.002). SDM was reported 
more frequently for men who had no health insurance (P < 0.001). In addition, men whose 
most recent PSA test occurred within the past year were more likely to report SDM than 
men who had the test done more than 2 years ago (P = 0.02).
Discussion
On the basis of the 2013 BRFSS data, our study suggests that SDM of prostate cancer 
screening remains substantially underused—only 36% among men who got screened. 
However, we found that men who had PSA testing within the past year were more likely to 
report shared decision-making than men who had the test more than 2 years ago. This might 
reflect an early improvement in conducting SDM in these three states. Recently published 
prostate cancer screening recommendations emphasizing the importance of SDM may 
partially account for the changes [2–5]. A national internet survey among patients who had 
prostate cancer screening discussions found the majority of final screening decisions which 
were made by either the health care provider or patient alone in 2011—only 34% of the 
decisions were made by patients and their health care provider together [9].
Given the uncertain effectiveness of PSA testing for reducing prostate cancer mortality, and 
the potential harms associated with diagnosing and treating prostate cancer cases that will 
not progress or progress slowly, SDM plays an important role in helping patients make 
decisions that are most consistent with their values and preferences. However, national 
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surveillance data showed that about 65% of all survey participants, who were aged 50–74 
years, had no screening discussion with their health care providers in 2010 [7]. Among men 
who had prostate screening discussions, most discussions addressed the advantages of PSA 
testing; fewer addressed the disadvantages of the test [8, 9]. According to the 2010 National 
Health Interview Survey data, only 27% of men aged 70 years or older who underwent PSA 
testing reported having discussions about both advantages and disadvantages of the test [10]. 
SDM before PSA testing has been underused between patients and their health care 
providers. Studies have indicated that decision-aids to help patients make informed decisions 
have been shown to improve their prostate cancer knowledge and reduce decision conflicts 
[11, 12]. Other potential strategies to promote SDM include changing outpatient clinic visit 
reimbursement, providing pre-visit decision support interventions, and physician education 
on value-concordant decision-making [13].
Our study suggested that men who had higher education, were married/living together, or 
had no health insurance were more likely to report having SDM before screening. Positive 
associations of higher education and married/living together with PSA testing have been 
reported, [10, 14]; however, their associations with SDM before PSA testing are 
understudied [7, 15]. Using the 2010 NHIS data, Han et al. reported that higher education 
and having private/military insurance were positively associated with discussion of 
uncertainty of PSA testing, but not discussion of advantages and disadvantages of the test 
[7]. Several factors may partially explain the differences between our findings and theirs: (1) 
our study population only included men who undertook a PSA test, instead of all men 
regardless of having the test; (2) we classified the health insurance variable as “Yes” or “No” 
instead of specifying insurance type; (3) we controlled marital status in the model, but they 
did not. More studies are needed to better understand the predictors for SDM, including 
education levels, and marital and health insurance status.
This study is subject to several limitations. First, the BRFSS data were self-reported and, 
thus, subject to recall bias. Second, low response rates increase the potential for selection 
bias; however, the calculations of weights, which were adjusted for differences in probability 
of selection and nonresponse, might have partially corrected the bias. Third, PSA testing 
may be underreported in the survey, because the test may have been conducted without the 
patient being told by his physician [16]. Fourth, this study has limited generalizability, 
because data were from three states. Finally, respondents might comprehend survey 
questions about prostate cancer screening decision-making differently [17]; thus, 
measurement errors could not be ruled out.
Conclusions
Although our data suggest that more SDM occurred in recent years, only one-third of men 
reported having SDM on prostate cancer screening with their health care provider in 
Delaware, Hawaii, and Massachusetts in 2013. Our study points to the need to promote 
SDM among patients and their health care providers before ordering a PSA test.
Li et al. Page 4
Cancer Causes Control. Author manuscript; available in PMC 2018 July 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Acknowledgments
The findings and conclusions in this report are those of the authors and do not necessarily represent the official 
position of CDC.
References
1. Force USPSTTalking With Your Patients About Screening for Prostate Cancer2012
2. Moyer VA. Force USPST. Screening for prostate cancer: U.S. Preventive Services Task Force 
recommendation statement. Ann Intern Med. 2012; 157:120–134. [PubMed: 22801674] 
3. Carter HB, Albertsen PC, Barry MJ, et al. Early Detection of Prostate Cancer: AUA Guideline. J 
Urol. 2013; 190:419–426. [PubMed: 23659877] 
4. Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P. Clinical Guidelines Committee of the 
American College of P. Screening for prostate cancer: a guidance statement from the Clinical 
Guidelines Committee of the American College of Physicians. Annals of internal medicine. 2013; 
158:761–769. [PubMed: 23567643] 
5. Smith RA, Manassaram-Baptiste D, Brooks D, et al. Cancer screening in the United States, 2014: a 
review of current American Cancer Society guidelines and current issues in cancer screening. CA 
Cancer J Clin. 2014; 64:30–51. [PubMed: 24408568] 
6. Knight SJ. Decision making and prostate cancer screening. Urol Clin North Am. 2014; 41:257–266. 
[PubMed: 24725488] 
7. Han PK, Kobrin S, Breen N, et al. National evidence on the use of shared decision making in 
prostate-specific antigen screening. Ann Fam Med. 2013; 11:306–314. [PubMed: 23835816] 
8. Hoffman RM, Couper MP, Zikmund-Fisher BJ, et al. Prostate cancer screening decisions: results 
from the National Survey of Medical Decisions (DECISIONS study). Arch Intern Med. 2009; 
169:1611–1618. [PubMed: 19786681] 
9. Hoffman RM, Elmore JG, Fairfield KM, Gerstein BS, Levin CA, Pignone MP. Lack of shared 
decision making in cancer screening discussions: results from a national survey. Am J Prev Med. 
2014; 47:251–259. [PubMed: 24923862] 
10. Li J, Berkowitz Z, Richards TB, Richardson LC. Shared decision making in prostate-specific 
antigen testing with men older than 70 years. Journal of the American Board of Family Medicine : 
JABFM. 2013; 26:401–408. [PubMed: 23833155] 
11. Taylor KL, Williams RM, Davis K, et al. Decision making in prostate cancer screening using 
decision aids vs usual care: a randomized clinical trial. JAMA Internal Med. 2013; 173:1704–
1712. [PubMed: 23896732] 
12. Volk RJ, Hawley ST, Kneuper S, et al. Trials of decision aids for prostate cancer screening: a 
systematic review. Am J Prev Med. 2007; 33:428–434. [PubMed: 17950409] 
13. Wilkes M, Srinivasan M, Cole G, Tardif R, Richardson LC, Plescia M. Discussing uncertainty and 
risk in primary care: recommendations of a multi-disciplinary panel regarding communication 
around prostate cancer screening. J Gen Internal Med. 2013; 28:1410–1419. [PubMed: 23649782] 
14. Li J, Zhao G, Hall IJ. Pre-screening discussions and prostate-specific antigen testing for prostate 
cancer screening. Am J Prev Med. 2015; 49:259–263. [PubMed: 25997905] 
15. McFall SL. US men discussing prostate-specific antigen tests with a physician. Ann Fam Med. 
2006; 4:433–436. [PubMed: 17003144] 
16. Chan EC, Vernon SW, Ahn C, Greisinger A. Do men know that they have had a prostate-specific 
antigen test? Accuracy of self-reports of testing at 2 sites. Am J Public Health. 2004; 94:1336–
1338. [PubMed: 15284039] 
17. Wunderlich T, Cooper G, Divine G, et al. Inconsistencies in patient perceptions and observer 
ratings of shared decision making: the case of colorectal cancer screening. Patient Educ Couns. 
2010; 80:358–363. [PubMed: 20667678] 
Li et al. Page 5
Cancer Causes Control. Author manuscript; available in PMC 2018 July 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Appendix 1
Prostate Cancer Screening Decision-Making Module.
1. Which one of the following best describes the decision to have the PSA test 
done?
A. You made the decision alone. [Go to next module].
B. Your doctor, nurse, or health care provider made the decision alone. [Go 
to next module].
C. You and one or more other persons made the decision together.
D. You do not remember how the decision was made. [Go to next module].
2. Who made the decision with you? (Mark all that apply).
A. Doctor, nurse, or health care provider.
B. Spouse or significant other.
C. Other family member.
D. Friend or nonrelative.
Appendix 2
Prostate Cancer Screening Module:
1. A Prostate-Specific Antigen test, also called a PSA test, is a blood test used to 
check men for prostate cancer. Has a doctor, nurse, or other health professional 
EVER talked with you about the advantages of the PSA test?
A. Yes.
B. No.
2. Has a doctor, nurse, or other health professional EVER talked with you about the 
disadvantages of the PSA test?
A. Yes.
B. No.
3. How long has it been since you had your last PSA test?
A. Within the past year (anytime less than 12 months ago).
B. Within the past 2 years (1 year but less than 2 years).
C. Within the past 3 years (2 years but less than 3 years).
D. Within the past 5 years (3 years but less than 5 years).
E. 5 or more years ago.
4. What was the main reason you had this PSA test – was it…?
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A. Part of routine exam.
B. Because of a prostate problem.
C. Because of a family history of prostate cancer.
D. Because you were told you had prostate cancer.
E. Some other reason.
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Table 1
Participant characteristics and weighted percentages for men who ever had a PSA test for cancer screening in 
Delaware, Hawaii, and Massachusetts, BRFSS 2013
Weighted % (n = 2,248; weighted N = 533,942)
Age
 40–54 years 25.8
 55–69 years 51.9
 70+ years 22.3
Race/ethnicity
 Non-Hispanic white 78.8
 Non-Hispanic black 6.1
 Hispanic 5.2
 Non-Hispanic other 9.9
Education
 ≥College graduate 45.4
 Some college 23.8
 High school graduate 23.6
 Less than high school 7.2
Employment
 Employed 57.0
 Unemployed 4.4
 Retired 32.8
 Others 5.8
Marital status
 Married or living together 77.8
 Divorced, separated, and widowed 14.3
 Never married 7.9
Smoking status
 Current 9.3
 Former or never 90.8
Regular exercise
 Yes 79.2
 No 20.8
Have health insurance
 Yes 98.0
 No 2.0
Have a primary doctor
 Yes 97.2
 No 2.8
Ever discussed advantages and disadvantages
 Yes 42.4
 No 57.6
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Li et al. Page 9
Weighted % (n = 2,248; weighted N = 533,942)
When had a PSA test
 Within a year 63.4
 1 year but less than 2 years 16.2
 2 years and more 20.4
Who made the decisions to obtain PSA testing
 Patient only 25.0
 Health care provider only 37.0
 Patient and health care provider 36.4
 Patient and othersa 1.6
PSA prostate-specific antigen
Percentages may not add to 100% because of rounding
aOthers include spouse or significant other, other family member, and friend or nonrelative
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